NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Highly Specialised Technology Evaluation

Eculizumab for the treatment of atypical haemolytic uraemic syndrome (aHUS)

Please sign and return to:

[redacted], Highly Specialised Technology Evaluation Project Manager
Email: [redacted]
Fax: [redacted]
Post: NICE, Level 1A, City Tower, Piccadilly Plaza, Manchester, M1 4BT

I confirm that:

- I agree with the content of the statement submitted by aHUS UK and consequently I will not be submitting a personal statement.

Name: LEN WOODWARD

Signed: [redacted]

Date: 14 OCTOBER 2013